RFK Jr. to speed up development and availability of low-cost alternatives to the costliest drugs
The Trump administration moved Wednesday to accelerate the development and availability of a broad class of low-cost, competitive drugs that promise to cut billions of dollars in U.S. spending on pharmaceuticals for diabetes, cancer and other conditions.
